Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Xenetic Biosciences Provides Update on Annual Meeting of Stockholders
Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders
Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
Xenetic Biosciences Announces Appointment of Three Directors to the Board
Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017
Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer
Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
